Sphere Medical

Commercialisation now begins

Update | 15 December 2016

Share this note

Sphere Medical has launched Proxima 4, a closed system for analysing a patient’s blood gases, across the key European markets. The direct sales team will address the UK, Germany, the Netherlands and Belgium, with their distributor marketing in Italy. A new distribution partner has been announced for Spain, with launch there expected in Q217. Further regional partnerships are expected during the coming year. This represents a landmark as Sphere Medical transitions towards commercialisation. We maintain our valuation, based on our DCF-based model, at £30.2m, equivalent to 21.3p per share.

Year-end: December201420152016E2017E
Sales (£m)
Adj. PBT (£m)(5.9)(6.0)(5.8)(5.6)
Net Income (£m)(5.3)(5.5)(4.7)(5.2)
Adj. EPS (p)(9.9)(5.3)(3.2)(3.5)
Cash (£m)3.710.03.06.6
EBITDA (£m)(5.8)(6.0)(5.7)(5.4)
Source: Trinity Delta Note: Adjusted numbers exclude share-based payments and exceptionals.
  • Proxima 4 launch marks transition to commercialisation Sphere Medical has launched its optimised Proxima 4 system in Europe. It is being marketed by the in-house sales team in the UK, Germany, the Netherlands, and Belgium. In Italy the local distributor, Burke & Burke, is also primed for launch. A new distributor, Proyectos Hospitalarios Internacional (Prhoinsa), has been appointed for Spain, with the launch there planned for Q217. Additional regional partners are expected to be confirmed during the coming year.
  • Addressing a wider patient population Proxima 4 is the latest generation of a proprietary micro-analyser technology platform that accurately and rapidly measures a variety of different blood parameters (including pH, pCO2, pO2, electrolytes and glucose) at the point of care (POC) in near-real time. Proxima 4 represents a major upgrade, with additional functionality and direct connectivity with hospital information systems, as well as simpler set-up. The target population for Proxima 4 is ~50% of patients in intensive care units, compared to ~12% for the earlier “beta” version (Proxima 3).
  • Commercial scale manufacture in place A dedicated full scale production site has been established in St. Asaph, Wales, and is now fully approved and operational. Launch stocks are ready for shipment, although timings suggest little revenue will fall in FY16. The site should have sufficient capacity to manufacture all of Proxima’s forecast needs for the near- and medium-term.
  • Gaining sales traction is the next major sensitivity We employ a three-phase DCF model; with appropriate adjustments for factors such as execution and regulatory risks. The granting of the CE Mark, in September, effectively removed regulatory risk from our investment case, shifting the focus onto management’s success in the execution of the marketing plans. Our valuation remains £30.2m (21.3p a share), with no changes to estimates.


14 July 2017

Price (Sterling)10.1p
Market Cap£14.3m
Enterprise Value£7.7m
Shares in issue141.8m
12 month range6.2-15.9p
Free float100%
Primary exchangeAIM London
Other exchangesNA
Company CodeSPHR.L
Corporate clientYes

Company description

Sphere Medical develops and commercialises medical monitoring and diagnostic equipment. Its lead product, Proxima, provides near real-time analysis of blood gases, electrolytes, and metabolites at the patient’s bedside within critical care.


Franc Gregori
+44 20 3637 5041

Mick Cooper PhD
+44 (0) 20 3637 5042

Exhibit 1: Summary of financials
Source: Sphere Medical, Trinity Delta Note: Adjusted numbers exclude share-based payments and exceptionals.


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2016 Trinity Delta Research Limited. All rights reserved.